429 related articles for article (PubMed ID: 27056886)
21. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer.
Toivonen R; Suominen E; Grenman R; Savontaus M
Oncol Rep; 2009 Jan; 21(1):165-71. PubMed ID: 19082458
[TBL] [Abstract][Full Text] [Related]
22. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
[TBL] [Abstract][Full Text] [Related]
23. Species D Adenoviruses as Oncolytic Viral Vectors.
Bullard BL; Corder BN; Weaver EA
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291224
[TBL] [Abstract][Full Text] [Related]
24. Improved adenovirus type 5 vector-mediated transduction of resistant cells by piggybacking on coxsackie B-adenovirus receptor-pseudotyped baculovirus.
Granio O; Porcherot M; Corjon S; Kitidee K; Henning P; Eljaafari A; Cimarelli A; Lindholm L; Miossec P; Boulanger P; Hong SS
J Virol; 2009 Jun; 83(12):6048-66. PubMed ID: 19357170
[TBL] [Abstract][Full Text] [Related]
25. CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice.
Mizuguchi H; Koizumi N; Hosono T; Ishii-Watabe A; Uchida E; Utoguchi N; Watanabe Y; Hayakawa T
Gene Ther; 2002 Jun; 9(12):769-76. PubMed ID: 12040458
[TBL] [Abstract][Full Text] [Related]
26. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.
Takagi-Kimura M; Yamano T; Tagawa M; Kubo S
Cancer Gene Ther; 2014 Mar; 21(3):126-32. PubMed ID: 24577130
[TBL] [Abstract][Full Text] [Related]
28. Targeting of high-capacity adenoviral vectors.
Biermann V; Volpers C; Hussmann S; Stock A; Kewes H; Schiedner G; Herrmann A; Kochanek S
Hum Gene Ther; 2001 Sep; 12(14):1757-69. PubMed ID: 11560769
[TBL] [Abstract][Full Text] [Related]
29. Improved gene transfer into bladder cancer cells using adenovirus vector containing RGD motif.
Hiwasa K; Nagaya H; Terao S; Acharya B; Hamada K; Mizuguchi H; Gotoh A
Anticancer Res; 2012 Aug; 32(8):3137-40. PubMed ID: 22843884
[TBL] [Abstract][Full Text] [Related]
30. Genetic incorporation of the protein transduction domain of Tat into Ad5 fiber enhances gene transfer efficacy.
Han T; Tang Y; Ugai H; Perry LE; Siegal GP; Contreras JL; Wu H
Virol J; 2007 Oct; 4():103. PubMed ID: 17958897
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus vectors composed of subgroup B adenoviruses.
Sakurai F; Kawabata K; Mizuguchi H
Curr Gene Ther; 2007 Aug; 7(4):229-38. PubMed ID: 17969556
[TBL] [Abstract][Full Text] [Related]
32. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation.
Schoggins JW; Nociari M; Philpott N; Falck-Pedersen E
J Virol; 2005 Sep; 79(18):11627-37. PubMed ID: 16140740
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice.
Ganesh S; Gonzalez-Edick M; Gibbons D; Waugh J; Van Roey M; Jooss K
Hum Gene Ther; 2009 Oct; 20(10):1201-13. PubMed ID: 19572803
[TBL] [Abstract][Full Text] [Related]
34. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
[TBL] [Abstract][Full Text] [Related]
35. A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth.
Yoon AR; Hong J; Yun CO
Oncotarget; 2015 Oct; 6(33):34875-91. PubMed ID: 26430798
[TBL] [Abstract][Full Text] [Related]
36. Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction.
Parker AL; White KM; Lavery CA; Custers J; Waddington SN; Baker AH
Gene Ther; 2013 Dec; 20(12):1158-64. PubMed ID: 24005577
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.
Ingemarsdotter CK; Tookman LA; Browne A; Pirlo K; Cutts R; Chelela C; Khurrum KF; Leung EY; Dowson S; Webber L; Khan I; Ennis D; Syed N; Crook TR; Brenton JD; Lockley M; McNeish IA
Mol Oncol; 2015 Apr; 9(4):791-805. PubMed ID: 25560085
[TBL] [Abstract][Full Text] [Related]
38. A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism.
Takayama K; Reynolds PN; Short JJ; Kawakami Y; Adachi Y; Glasgow JN; Rots MG; Krasnykh V; Douglas JT; Curiel DT
Virology; 2003 May; 309(2):282-93. PubMed ID: 12758175
[TBL] [Abstract][Full Text] [Related]
39. Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors.
Nakamura T; Sato K; Hamada H
Hum Gene Ther; 2002 Mar; 13(5):613-26. PubMed ID: 11916485
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic adenovirus based on serotype 3.
Hemminki O; Bauerschmitz G; Hemmi S; Lavilla-Alonso S; Diaconu I; Guse K; Koski A; Desmond RA; Lappalainen M; Kanerva A; Cerullo V; Pesonen S; Hemminki A
Cancer Gene Ther; 2011 Apr; 18(4):288-96. PubMed ID: 21183947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
